During this year´s AACR Annual Meeting, Washington DC, April 6 -10, ecancer caught up with VHIO´s Laura Soucek, PI of the Mouse Models of Cancer Therapies Group, to discuss her group´s pioneering work on Myc inihibition in pre-clinical mouse models.
Related Posts
Presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO), May 30 – June 03, Chicago IL, USA, the Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO) have participated in an international phase III study published in the New England Journal of Medicine. Findings show that the administration of the drug enzalutamide prior to chemotherapy in metastatic prostate cancer patients reduces disease progression of by 81% — consequently postponing initiation of treatment with the latter, and leading to increased survival and improved quality of life for patients.
A recent paper published in The New England Journal of Medicine, shows that Pertuzumab, an anti-HER 2 antibody, recognizes a different epitope of HER2 than Trastuzumab and behaves differently. In patients with metastatic breast cancer, the combination of the two antibodies plus docetaxel significantly increased progression-free survival.
Co-author Javier Cortés, Principle Investigator of VHIO´s Breast Cancer and Melanoma Group, describes the CLEOPATRA (CLinical Evaluation Of Pertuzumab And TRAstuzumab) randomized trial, the importance and implications of the findings, as well as signposts future directions.
Abstract submission deadline, close of business Monday 18 April, is rapidly approaching. The next couple of days represent the final…
Inés Gasén was diagnosed with breast cancer during her pregnancy – not only naturally provoking fear and uncertainty for her…
Cancer researchers, oncologists and international pharmaceutical company join forces to test a new investigational drug for breast cancer Barcelona, 05…
• GSK undertakes global consortium incorporating six prestigious cancer research centers • The Oncology Clinical and Translational Consortium (OCTC) includes…
Source: The European Society for Medical Oncology (ESMO) Lugano, Switzerland, 27 August 2015 — The European Society for Medical Oncology…
Celebrated last week during the 2015 Annual Meeting of the American Society of Clinical Oncology (ASCO), Cristina Cruz receives a…
VHIO and 27 other leading European Cancer Institutes are working together in a unique collaboration to share infrastructures and collaborate on projects to help advance cancer research and treatment: EurocanPlatform
It is with deep regret and sadness that we write to report the passing of one of the greatest supporters…
Showcased during AACR´s 2017 Annual Meeting´s Opening Plenary: The Road to Cancer Cures – Discover, Predict, Prevent and Treat, Sunday…
Last week ´s seventh El Paseíco de la Mama 7.5 Km sponsored walk along Zaragoza´s canal will raise essential funding…
• Various research lines led by VHIO aim at better deciphering how tumor cells acquire resistance to anticancer agents including…
Comprised of AICR (now rebranded as Worldwide Cancer Research) donors, supporters, staff and AICR grant holders, some 15 individuals, including VHIO´s…
IMPORTANT NOTIFICATION: As an update to this earlier news item (see below), Pau´s fundraising concert on the 22nd December is…